{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:17:59Z","timestamp":1788347879304,"version":"build-2803163510"},"reference-count":37,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ivarmacitinib, an oral JAK1 inhibitor, improved efficacy outcomes versus placebo at Week 16 in a phase 3 trial in patients with moderate\u2010to\u2010severe atopic dermatitis (AD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe efficacy and safety outcomes through Week 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicentre, double\u2010blind, phase 3 trial (NCT04875169), patients aged 12\u201375\u2009years were randomized 1:1:1 to receive once\u2010daily oral ivarmacitinib 4\u2009mg, ivarmacitinib 8\u2009mg, or placebo for 16\u2009weeks, followed by a 36\u2010week double\u2010blind extension. At Week 16, placebo\u2010treated patients who continued in the study were re\u2010randomized to ivarmacitinib 4\u2009mg or 8\u2009mg. Key Week 52 endpoints included Investigator's Global Assessment (IGA) 0\/1 with at least a 2\u2010grade improvement, Eczema Area and Severity Index 75 (EASI\u201075), and Worst Itch Numeric Rating Scale (WI\u2010NRS) response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 336 randomized patients, 258 completed 52\u2009weeks of treatment. Among patients initially randomized to ivarmacitinib, Week 52 IGA responses were achieved by 42.3% and 40.2% of patients in the 4\u2009mg and 8\u2009mg groups, respectively. EASI\u201075 responses were achieved by 60.6% and 55.9%, and WI\u2010NRS responses by 59.6% and 45.1%, respectively. During the active\u2010treatment period, treatment\u2010emergent adverse events (TEAEs) occurred in 87.5% and 85.5% of patients in the 4\u2009mg and 8\u2009mg groups, respectively. The most frequent TEAEs were upper respiratory tract infection, COVID\u201019, SARS\u2010CoV\u20102 test positive, and increased blood creatine phosphokinase. Serious TEAEs occurred in 5.6% and 4.4% of patients, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ivarmacitinib was associated with generally maintained improvement through Week 52, with a safety profile generally consistent with that observed during the placebo\u2010controlled period. Because the extension phase had no placebo control after Week 16, long\u2010term efficacy findings should be interpreted as descriptive.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70710","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:01:36Z","timestamp":1788346896000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["52\u2010week ivarmacitinib in moderate\u2010to\u2010severe atopic dermatitis: A phase 3 trial"],"prefix":"10.1111","author":[{"given":"Yan","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Dermatology Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[{"name":"SKiN Centre for Dermatology  Peterborough Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dermatology Hospital Southern Medical University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology Wuhan No. 1 Hospital  Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology The First People's Hospital of Hangzhou  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Jing","family":"Loo","sequence":"additional","affiliation":[{"name":"DermEffects  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Toth","sequence":"additional","affiliation":[{"name":"XLR8 Medical Research  Windsor Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5605-3844","authenticated-orcid":false,"given":"Maxwell","family":"Sauder","sequence":"additional","affiliation":[{"name":"Toronto Research Centre  Waterloo Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1320-366X","authenticated-orcid":false,"given":"Jingyi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Dermatology Zhejiang Provincial People's Hospital  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyun","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, the Third Xiangya Hospital Central South University  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Southwest Hospital Army Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiande","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Dermatology, the First Affiliated Hospital Sun Yat\u2010Sen University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology Guangdong Provincial Hospital of Traditional Chinese Medicine  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Research and Development Jiangsu Hengrui Pharmaceuticals Co., Ltd.  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Research and Development Jiangsu Hengrui Pharmaceuticals Co., Ltd.  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-682X","authenticated-orcid":false,"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/jdv.20639","article-title":"European Guideline (EuroGuiDerm) on atopic eczema: Living update","volume":"39","author":"Wollenberg A","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_13_3_1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.5694\/mja2.51560","article-title":"Management of atopic dermatitis: a narrative review","volume":"216","author":"Goh MS","year":"2022","journal-title":"Med J Aust"},{"key":"e_1_2_13_4_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra2023911","article-title":"Atopic dermatitis","volume":"384","author":"St\u00e4nder S","year":"2021","journal-title":"N Engl J Med"},{"key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate\u2010to\u2010severe atopic dermatitis","volume":"371","author":"Beck LA","year":"2014","journal-title":"N Engl J Med"},{"key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate\u2010to\u2010severe atopic dermatitis: results from two 52\u2010week, randomized, double\u2010blind, multicentre, placebo\u2010controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg A","year":"2021","journal-title":"Br J Dermatol"},{"key":"e_1_2_13_7_1","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of Lebrikizumab for moderate\u2010to\u2010severe atopic dermatitis","volume":"388","author":"Silverberg JI","year":"2023","journal-title":"N Engl J Med"},{"key":"e_1_2_13_8_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long\u2010term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open\u2010label extension study","volume":"82","author":"Deleuran M","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bjd\/ljad022","article-title":"Efficacy and safety of lebrikizumab in moderate\u2010to\u2010severe atopic dermatitis: 52\u2010week results of two randomized double\u2010blinded placebo\u2010controlled phase III trials","volume":"188","author":"Blauvelt A","year":"2023","journal-title":"Br J Dermatol"},{"key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/jcm11154431","article-title":"The JAK\/STAT pathway and its selective inhibition in the treatment of atopic dermatitis: a systematic review","volume":"11","author":"Tsiogka A","year":"2022","journal-title":"J Clin Med"},{"key":"e_1_2_13_11_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in dermatology","volume":"10","author":"Solimani F","year":"2019","journal-title":"Front Immunol"},{"key":"e_1_2_13_12_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK\u2010STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review","volume":"13","author":"Huang IH","year":"2022","journal-title":"Front Immunol"},{"key":"e_1_2_13_13_1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nrd.2017.204","article-title":"Neuroimmunological disorders: JAK in the itch","volume":"16","author":"Bordon Y","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_2_13_14_1","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once\u2010daily upadacitinib versus placebo in adolescents and adults with moderate\u2010to\u2010severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double\u2010blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman\u2010Yassky E","year":"2021","journal-title":"Lancet"},{"key":"e_1_2_13_15_1","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of Baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Reich K","year":"2020","journal-title":"JAMA Dermatol"},{"key":"e_1_2_13_16_1","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/jdv.19280","article-title":"Abrocitinib efficacy and safety in patients with moderate\u2010to\u2010severe atopic dermatitis: results from phase 3 studies, including the long\u2010term extension JADE EXTEND study","volume":"37","author":"Reich K","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_13_17_1","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/jdv.18816","article-title":"Long\u2010term efficacy (up to 68\u2009weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate\u2010to\u2010severe atopic dermatitis: analysis of treatment responders, partial responders and nonresponders originating from study BREEZE\u2010AD7","volume":"37","author":"Silverberg JI","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_13_18_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate\u2010to\u2010severe atopic dermatitis (JADE MONO\u20101): a multicentre, double\u2010blind, randomised, placebo\u2010controlled, phase 3 trial","volume":"396","author":"Simpson EL","year":"2020","journal-title":"Lancet"},{"key":"e_1_2_13_19_1","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljad162.047","article-title":"427 long\u2010term 4\u2010year safety of upadacitinib in moderate\u2010to\u2010severe atopic dermatitis: results of an integrated analysis of phase 3 studies","volume":"188","author":"Silverberg JI","year":"2023","journal-title":"Br J Dermatol"},{"key":"e_1_2_13_20_1","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12072701","article-title":"Overview of atopic dermatitis in different ethnic groups","volume":"12","author":"Chiricozzi A","year":"2023","journal-title":"J Clin Med"},{"key":"e_1_2_13_21_1","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/jamadermatol.2025.0982","article-title":"Ivarmacitinib for moderate to severe atopic dermatitis in adults and adolescents: a phase 3 randomized clinical trial","volume":"161","author":"Zhao Y","year":"2025","journal-title":"JAMA Dermatol"},{"key":"e_1_2_13_22_1","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jaci.2022.10.023","article-title":"Novel insights into atopic dermatitis","volume":"151","author":"Schuler CF","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_13_23_1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","article-title":"Atopic dermatitis","volume":"405","author":"Guttman\u2010Yassky E","year":"2025","journal-title":"Lancet"},{"key":"e_1_2_13_24_1","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","article-title":"The Children's dermatology life quality index (CDLQI): initial validation and practical use","volume":"132","author":"Lewis\u2010Jones MS","year":"1995","journal-title":"Br J Dermatol"},{"key":"e_1_2_13_25_1","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","article-title":"The patient\u2010oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective","volume":"140","author":"Charman CR","year":"2004","journal-title":"Arch Dermatol"},{"key":"e_1_2_13_26_1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology life quality index (DLQI)\u2010\u2010a simple practical measure for routine clinical use","volume":"19","author":"Finlay AY","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"e_1_2_13_27_1","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40257-021-00627-2","article-title":"Efficacy and safety of SHR0302, a highly selective Janus kinase 1 inhibitor, in patients with moderate to severe atopic dermatitis: a phase II randomized clinical trial","volume":"22","author":"Zhao Y","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"e_1_2_13_28_1","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljad113.109","article-title":"P81 long\u2010term efficacy of abrocitinib in adolescents and adults with moderate\u2010to\u2010severe atopic dermatitis: a post hoc analysis of JADE EXTEND","volume":"188","author":"Paller AS","year":"2023","journal-title":"Br J Dermatol"},{"key":"e_1_2_13_29_1","first-page":"e407","article-title":"Effectiveness and safety of upadacitinib in adolescent and adult patients with atopic dermatitis: an analysis of long\u2010term (week 52) data from a real\u2010world multicenter retrospective review","volume":"36","author":"Sood S","year":"2024","journal-title":"Br J Dermatol"},{"key":"e_1_2_13_30_1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s13555-017-0192-3","article-title":"Frequency and Management of Sleep Disturbance in adults with atopic dermatitis: a systematic review","volume":"7","author":"Jeon C","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"e_1_2_13_31_1","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/DER.0000000000000687","article-title":"High levels of psychological distress, sleep disturbance, and alcohol use disorder in adults with atopic dermatitis","volume":"32","author":"Gilhooley E","year":"2021","journal-title":"Dermatitis"},{"key":"e_1_2_13_32_1","doi-asserted-by":"crossref","first-page":"ii32","DOI":"10.1093\/bjd\/ljad498.035","article-title":"530 \u2010 treatment efficacy in patients with moderate\u2010to\u2010severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long\u2010term extension study","volume":"190","author":"Gooderham MJ","year":"2024","journal-title":"Br J Dermatol"},{"key":"e_1_2_13_33_1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and safety of Upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow\u2010up data from the measure up 1 and measure up 2 randomized clinical trials","volume":"158","author":"Simpson EL","year":"2022","journal-title":"JAMA Dermatol"},{"key":"e_1_2_13_34_1","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.063","article-title":"A randomized, double\u2010blind, placebo\u2010controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate\u2010to\u2010severe alopecia areata","volume":"89","author":"Zhou C","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_13_35_1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/ard-2024-226385","article-title":"Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate\u2010to\u2010severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial","volume":"84","author":"Liu J","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_13_36_1","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1053\/j.gastro.2022.08.007","article-title":"Efficacy and safety of Ivarmacitinib in patients with moderate\u2010to\u2010severe, active, ulcerative colitis: a phase II study","volume":"163","author":"Chen B","year":"2022","journal-title":"Gastroenterology"},{"key":"e_1_2_13_37_1","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/jdv.70172","article-title":"Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6\u2009years","volume":"40","author":"Bunick CG","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_13_38_1","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya R","year":"2021","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70710","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70710","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:01:43Z","timestamp":1788346903000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":37,"alternative-id":["10.1111\/jdv.70710"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70710","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"2025-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jdv.70710"}}